We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$197M
Cap. Flow %
3.49%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.44%
2 Miscellaneous 16.52%
3 Consumer Discretionary 8.71%
4 Technology 1.72%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
76
Agenus
AGEN
$322M
$16.3M 0.29%
305,700
-45,855
-13% -$3.31M
BBIO icon
77
BridgeBio Pharma
BBIO
$13.4B
$15.4M 0.27%
250,000
-50,000
-17% -$3.27M
KWEB icon
78
CALL
KraneShares CSI China Internet ETF
KWEB
$4.68B
$15.3M 0.27%
+200,000
New +$17.5M
NBTX
79
Nanobiotix
NBTX
$1.79B
$15M 0.27%
1,000,000
– –
ADAG
80
Adagene
ADAG
$199M
$14.4M 0.25%
+800,000
New +$18.2M
ZYME icon
81
Zymeworks
ZYME
$1.86B
$14.2M 0.25%
450,000
+100,000
+29% +$4.06M
RLAY icon
82
Relay Therapeutics
RLAY
$4.16B
$13.8M 0.24%
400,000
– –
SANA icon
83
Sana Biotechnology
SANA
$946M
$13.4M 0.24%
+400,000
New +$13M
YI
84
111 Inc
YI
$30.7M
$13.3M 0.24%
96,635
-3,365
-3% -$489K
ORTX
85
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$13.1M 0.23%
180,386
+145,236
+413% +$10.3M
AUPH icon
86
Aurinia Pharmaceuticals
AUPH
$2.15B
$13M 0.23%
1,000,000
– –
Z icon
87
Zillow
Z
$7.31B
$13M 0.23%
100,000
-450,000
-82% -$66.8M
IOVA icon
88
Iovance Biotherapeutics
IOVA
$4.24B
$12.7M 0.22%
400,000
– –
SLDB icon
89
Solid Biosciences
SLDB
$897M
$12.4M 0.22%
+150,000
New +$16.6M
MRNS
90
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.4M 0.22%
800,000
+500,000
+167% +$7.23M
YMAB
91
DELISTED
Y-mAbs Therapeutics
YMAB
$12.1M 0.21%
400,000
+114,972
+40% +$4.71M
DSGN icon
92
Design Therapeutics
DSGN
$765M
$12M 0.21%
+400,000
New +$13.5M
BMRN icon
93
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
$11.3M 0.2%
150,000
– –
TIL icon
94
Instil Bio
TIL
$48.9M
$11.3M 0.2%
+22,500
New +$11.5M
TME icon
95
Tencent Music
TME
$12.9B
$11.3M 0.2%
+550,000
New +$14M
IMUX icon
96
Immunic
IMUX
$141M
$11.2M 0.2%
70,000
– –
EVLO
97
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$10.7M 0.19%
50,000
+15,000
+43% +$4.15M
OVID icon
98
Ovid Therapeutics
OVID
$529M
$10.1M 0.18%
2,500,000
– –
TCOM icon
99
Trip.com Group
TCOM
$24.7B
$9.91M 0.18%
250,000
-250,000
-50% -$9.26M
KYMR icon
100
Kymera Therapeutics
KYMR
$9.41B
$9.71M 0.17%
250,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $197M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.